Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florentien E M In 't Hout

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Haematologica|August 24, 2014
High expression of transcription factor 4 (TCF4) is an independent adverse prognostic factor in acute myeloid leukemia that could guide treatment decisionsFlorentien E M in 't Hout, Bert A van der Reijden, Davide Monteferrario, et al.
Annals of Surgery|May 9, 2012
Prognostic importance of the extent of ulceration in patients with clinically localized cutaneous melanomaFlorentien E M In 't Hout, Lauren E Haydu, Rajmohan Murali, et al.
Nederlands Tijdschrift Voor Geneeskunde|May 24, 2019
[Medicinal cannabis]Geke A H van den Elsen, Florentien E M In 't Hout, Marjan de Vries, et al.
Leukemia|December 12, 2024
Acute myeloid leukemia associated RUNX1 variants induce aberrant expression of transcription factor TCF4Mylène Gerritsen, Florentien E M In 't Hout, Ruth Knops, et al.
Experimental Hematology|October 14, 2018
TCF4 promotes erythroid developmentFlorentien E M In 't Hout, Jolanda van Duren, Davide Monteferrario, et al.
British Journal of Haematology|March 25, 2021
Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)-mutant myelodysplastic syndromes subtypeCarolien Duetz, Theresia M Westers, Florentien E M In 't Hout, et al.
Oncoimmunology|March 5, 2016
Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccinationKalijn F Bol, Erik H J G Aarntzen, Florentien E M In 't Hout, et al.
Hemasphere|January 6, 2025
High levels of global hydroxymethylation predict worse overall survival in MDS patients treated with azacitidineFrancesca Tiso, Florentien E M In 't Hout, Ruth Knops, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Haematologica|August 24, 2014
High expression of transcription factor 4 (TCF4) is an independent adverse prognostic factor in acute myeloid leukemia that could guide treatment decisionsFlorentien E M in 't Hout, Bert A van der Reijden, Davide Monteferrario, et al.
Annals of Surgery|May 9, 2012
Prognostic importance of the extent of ulceration in patients with clinically localized cutaneous melanomaFlorentien E M In 't Hout, Lauren E Haydu, Rajmohan Murali, et al.
Nederlands Tijdschrift Voor Geneeskunde|May 24, 2019
[Medicinal cannabis]Geke A H van den Elsen, Florentien E M In 't Hout, Marjan de Vries, et al.
Leukemia|December 12, 2024
Acute myeloid leukemia associated RUNX1 variants induce aberrant expression of transcription factor TCF4Mylène Gerritsen, Florentien E M In 't Hout, Ruth Knops, et al.
Experimental Hematology|October 14, 2018
TCF4 promotes erythroid developmentFlorentien E M In 't Hout, Jolanda van Duren, Davide Monteferrario, et al.
British Journal of Haematology|March 25, 2021
Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)-mutant myelodysplastic syndromes subtypeCarolien Duetz, Theresia M Westers, Florentien E M In 't Hout, et al.
Oncoimmunology|March 5, 2016
Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccinationKalijn F Bol, Erik H J G Aarntzen, Florentien E M In 't Hout, et al.
Hemasphere|January 6, 2025
High levels of global hydroxymethylation predict worse overall survival in MDS patients treated with azacitidineFrancesca Tiso, Florentien E M In 't Hout, Ruth Knops, et al.
Pageof 1